(Corrects paragraph 5 in February 5 story to say 2025 Prolia sales were $4.4 billion, not $1.05 billion) Feb 5 (Reuters) - ...
CVS Health Inc. CVS on Thursday said it is taking additional steps to lower prescription drug costs by expanding access to ...
CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity and ...
CVS Caremark identified four pipeline drugs that could reshape care delivery in 2026, with potential FDA approvals spanning weight management, diabetes, breast cancer and emergency allergy treatment.
A House committee found that CVS Health may have violated federal antitrust laws by threatening independent pharmacies to keep them from using money-saving services outside the company’s pharmacy ...
CVS Health® (NYSE: CVS) today announced new steps to further help customers expand adoption of lower-cost biosimilar medications. Effective April 1, 2026, CVS Caremark will begin offering osteoporosis ...
House committee accuses CVS of impeding pharmacy competition by restricting independent pharmacies and calls for legislative ...
The company’s massive pharmacy benefit manager changed its rules and weaponized audits to ensure independent pharmacies ...
The legislation will impose new restrictions on pharmacy benefit managers, giant companies like CVS Caremark, Optum Rx and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results